Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma

Next Previous
Trial Profile

Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
  • Indications Carcinoma; Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms PORTEC-3

Most Recent Events

  • 10 Oct 2023 Planned End Date changed from 31 Dec 2027 to 31 Dec 2024.
  • 04 Apr 2022 Planned End Date changed from 1 Dec 2027 to 31 Dec 2027
  • 01 Feb 2022 Results investigating whether IMRT, compared to 3DCRT, resulted in fewer adverse events and patient-reported symptoms, published in the International Journal of Radiation Oncology, Biology, Physics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top